

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC. 20549**

**SCHEDULE 14A  
(Rule 14A-101)**

**INFORMATION REQUIRED IN PROXY STATEMENT  
SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of  
the Securities Exchange Act of 1934

Filed by the Registrant   
Filed by a Party other than the Registrant  
Check the appropriate box:

- |                                     |   |                          |  |
|-------------------------------------|---|--------------------------|--|
| <input type="checkbox"/>            | Preliminary Proxy Statement                                   | <input type="checkbox"/> | Confidential, for Use of the Commission Only<br>(as permitted by Rule 14a-6(e)(2)) |
| <input type="checkbox"/>            | Definitive Proxy Statement                                    |                          |  |
| <input checked="" type="checkbox"/> | Definitive Additional Materials                               |                          |  |
| <input type="checkbox"/>            | Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12 |                          |  |

---

**LEXICON PHARMACEUTICALS, INC.**

(Name of Registrant as Specified In Its Charter)

---

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
- (1) Title of each class of securities to which transaction applies: N/A
  - (2) Aggregate number of securities to which transaction applies: N/A
  - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): N/A
  - (4) Proposed maximum aggregate value of transaction: N/A
  - (5) Total fee paid: \$0
- Fee paid previously with preliminary materials: N/A
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
- (1) Amount Previously Paid:
  - (2) Form, Schedule or Registration Statement No.:
  - (3) Filing Party:
  - (4) Date Filed

**\*\*\* Exercise Your *Right* to Vote \*\*\***  
**Important Notice Regarding the Availability of Proxy Materials for the  
Shareholder Meeting to be Held on April 23, 2015**

**LEXICON PHARMACEUTICALS, INC.**

LEXICON PHARMACEUTICALS, INC.  
8800 TECHNOLOGY FOREST PLACE  
THE WOODLANDS, TX 77381

**Meeting Information**

**Meeting Type:** Annual Meeting  
**For holders as of:** February 23, 2015  
**Date:** April 23, 2015      **Time:** 8:00 AM CDT  
**Location:** Lexicon Pharmaceuticals, Inc.  
8800 Technology Forest Place  
The Woodlands, TX

You are receiving this communication because you hold shares in the above named company.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at [www.proxyvote.com](http://www.proxyvote.com) or easily request a paper copy (see reverse side)

We encourage you to access and review all of the important information contained in the proxy materials before voting

**See the reverse side of this notice to obtain proxy materials and voting instructions**

**— BEFORE YOU VOTE —**  
How to Access the Proxy Materials

**Proxy Materials Available to VIEW or RECEIVE:**

Notice & Proxy Statement Annual Report

**How to View Online:**

Have the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX XXXX (located on the following page) and visit:

[www.proxyvote.com](http://www.proxyvote.com)

**How to Request and Receive a PAPER or E-MAIL Copy:**

If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request:

- 1) BY INTERNET: [www.proxyvote.com](http://www.proxyvote.com)
- 2) BY TELEPHONE: 1-800-579-1639
- 3) BY EMAIL\*: [sendmaterial@proxyvote.com](mailto:sendmaterial@proxyvote.com)

\* If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX XXXX (located on the following page) in the subject line.

Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before April 09, 2015 to facilitate timely delivery.

**— HOW TO VOTE —**

Please Choose One of The Following Voting Methods

**Vote in Person:** Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the Meeting you will need to request a ballot to vote these shares.

**Vote by Internet:** To vote now by Internet, go to [www.proxyvote.com](http://www.proxyvote.com). Have the information that is printed in the box marked by the arrow ð XXXX XXXX XXXX XXXX available and follow the instructions.

**Vote by Mail:** You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

<b>Voting items</b>
---------------------

**The Board of Directors recommends that you vote FOR the following:**

1. Election of Directors

**Nominees:**

01) Philippe J. Amouyal

02) Lonnel Coats

03) Frank P. Palantoni

**The Board of Directors recommends you vote FOR proposals 2 through 6:**

2. Approval of an amendment to the Company's amended and restated certificate of incorporation to effect, at the discretion of the board of directors: a reverse split of the Company's common stock, in a range of 1-for-6 to 1-for-10 and a reduction in the number of authorized shares of the Company's common stock from 900,000,000 to a range of 265,000,000 to 160,000,000
3. Ratification and approval of the amendment to the Company's Equity Incentive Plan
4. Ratification and approval of the amendment to the Company's Non-Employee Directors' Equity Incentive Plan
5. Advisory vote to approve the compensation paid to the Company's named executive officers
6. Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent auditors for the fiscal year ending December 31, 2015

**NOTE:** In their discretion, upon such other matters that may properly come before the meeting or any adjournment thereof.